LY03017

LY03017
Clinical data
Other namesLY-03017; LPM-526000133; LPM526000133
Routes of
administration		Oral[1][2]
Drug classSerotonin 5-HT2 receptor antagonist; Serotonin 5-HT2A receptor inverse agonist; Serotonin 5-HT2C receptor antagonist

LY03017, also known as LPM-526000133, is a serotonin 5-HT2 receptor antagonist which is under development for the treatment of schizophrenia[1][3][2] and Alzheimer's psychosis.[4] It acts specifically as a dual serotonin 5-HT2A receptor inverse agonist and serotonin 5-HT2C receptor antagonist.[1][3][2] The drug is under development by Luye Pharma Group in China.[1][3] As of December 2025, it is in phase 1 clinical trials.[1][3][2] The chemical structure of LY03017 does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f "LY 03017". AdisInsight. 31 December 2025. Retrieved 31 January 2026.
  2. ^ a b c d "LY-03017 Drug Profile". Ozmosi. 1 January 1900. Retrieved 31 January 2026.
  3. ^ a b c d "Delving into the Latest Updates on LPM526000133 with Synapse". Synapse. 24 January 2026. Retrieved 31 January 2026.
  4. ^ Alhawarri MB (October 2025). "Hypothesis-Driven Insights and Clinical Trial Updates in Alzheimer's Disease Pathogenesis". CNS & Neurological Disorders Drug Targets. doi:10.2174/0118715273387383250924031644. PMID 41126430.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.